A group of world renowned business magnates provided $7M in financing to ProMIS and stated that their due diligence indicates the technology has tremendous potential. This investment will be used to transition PMN310 into Phase 1 clinical trials for treatment of Alzheimer's disease, one of the biggest unmet needs in the world.

https://www.globenewswire.com/news-release/2021/03/22/2197066/0/en/ProMIS-Neurosciences-Completes-US-7M-CDN-8-75M-Financing-with-Distinguished-Group-of-Boston-Based-Investors.html

LaBron James might become an indirect investor in ProMIS as well, haha...
https://www.bostonglobe.com/2021/03/16/sports/fenway-sports-group-adds-lebron-james-partner-approves-deal-jump-start-plan-acquire-more-teams/

One of our partners who is developing a COVID serology assay that rapidly analyzes and classifies antibodies is now officially taking patient referrals for testing. The test is described as 'awaiting accreditation,' likely indicating that accreditation is actively being sought. This assay is unique in its ability to distinguish antibodies that may correlate with immunity.
https://bcneuro.ca/wp-content/uploads/2021/03/Req-2.5-March-2021.pdf